Sun Pharmaceuticals
SC blasts manner of stalling Sun-Ranbaxy merger
21 May 2014
Sun Pharma denied the charge but said the share purchase by Silver Street, a limited-liability partnership firm owned by two subsidiaries of Sun Pharma, was being annulled
HC blocks Ranbaxy-Sun Pharma merger over insider trading allegations
30 Apr 2014
The order was in response to a petition for a Sebi inquiry into possible insider trading in Ranbaxy shares that saw heavy trading before the merger with Sun Pharma was announced
Ranbaxy drug flows to Europe, US to dry up
09 Apr 2014
Sun Pharmaceutical Industries plans to phase out sales of Ranbaxy’s branded generic drugs in the US while continuing sales in other markets
Sun Pharma, Ranbaxy to merge in Rs24,000 all-stock deal
07 Apr 2014
The merger will create India's largest pharmaceutical company and the world's fifth largest speciality generics company with annual emerging market sales nearing Rs6,000 crore
And now, USFDA bans imports from Sun Pharma unit
13 Mar 2014
The US regulator has been cracking down heavily on Indian generic pharmaceutical firms such as Ranbaxy and Wockhardt for alleged failure to comply with its manufacturing norms
Teva, Sun Pharma to pay Pfizer $2.15 bn to settle patent suit
12 Jun 2013
Teva, the world’s largest generic drug firm, will pay $1.6 billion of the settlement amount while Sun Pharmaceuticals will pay the remaining $550 million
Sun Pharma in discussion to acquire controlling stake in Meda AB
31 May 2013
Sun Pharmaceutical Industries is in discussions to acquire a controlling stake in Swedish drugmaker Meda AB for around $5 billion to boost its generics business in developed markets
Sun Pharma calls off $600-million buyout of Taro
08 Feb 2013
Sun Pharma's latest buyout offer of $39.50 per share for 15 million scrips was 61 per cent higher than its previous offer of $24.50, which Taro had rejected
Sun Pharma’s US unit to buy URL Pharma
18 Dec 2012
Sun Pharma to buy out Israel’s Taro for $571 million
13 Aug 2012
Taro Pharmaceutical Industries has agreed to a new offer of Sun Pharma, which already owns 66.3 per cent of Taro, to pay $39.50 per share for the remaining stake held by Taro’s minority shareholders
Israel’s Taro rejects Sun Pharma’s $367-mn buyout offer
20 Jul 2012
Mumbai-based Sun Pharma, India's largest pharmaceutical company by market capitalisation, already owns 66.3 per cent of Taro
Featured articles
The remarkable Ratan Tata
By Kiron Kasbekar | 23 Oct 2024
One newspaper report of Ratan Tata’s passing away showed an old photo of him climbing into the cockpit of a Lockheed Martin F-16 fighter.
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation